OBJECTIVE: The purpose of this study was to reduce the time to tumor onset in a diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) swine model via partial liver embolization (PLE) and to characterize the model for use in translational research. METHODS: Eight Yucatan miniature pigs were injected intraperitoneally with either saline (n = 2) or DEN (n = 6) solution weekly for 12 weeks. Three of the DEN-treated pigs underwent PLE. The animals underwent periodic radiological evaluation, liver biopsy, and blood sampling, and full necropsy was performed at study termination (∼29 months). RESULTS: All DEN-treated pigs developed hepatic adenoma and HCC. PLE accelerated the time to adenoma development but not to HCC development. Biomarker analysis results showed that IGF1 levels decreased in all DEN-treated pigs as functional liver capacity decreased with progression of HCC. VEGF and IL-6 levels were positively correlated with disease progression. Immunohistochemical probing of HCC tissues demonstrated the expression of several important survival-promoting proteins. CONCLUSION: To our knowledge, we are the first to demonstrate an accelerated development of hepatic neoplasia in Yucatan miniature pigs. Our HCC swine model closely mimics the human condition (i.e., progressive disease stages and expression of relevant molecular markers) and is a viable translational model.
OBJECTIVE: The purpose of this study was to reduce the time to tumor onset in a diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC)swine model via partial liver embolization (PLE) and to characterize the model for use in translational research. METHODS: Eight Yucatan miniature pigs were injected intraperitoneally with either saline (n = 2) or DEN (n = 6) solution weekly for 12 weeks. Three of the DEN-treated pigs underwent PLE. The animals underwent periodic radiological evaluation, liver biopsy, and blood sampling, and full necropsy was performed at study termination (∼29 months). RESULTS: All DEN-treated pigs developed hepatic adenoma and HCC. PLE accelerated the time to adenoma development but not to HCC development. Biomarker analysis results showed that IGF1 levels decreased in all DEN-treated pigs as functional liver capacity decreased with progression of HCC. VEGF and IL-6 levels were positively correlated with disease progression. Immunohistochemical probing of HCC tissues demonstrated the expression of several important survival-promoting proteins. CONCLUSION: To our knowledge, we are the first to demonstrate an accelerated development of hepatic neoplasia in Yucatan miniature pigs. Our HCCswine model closely mimics the human condition (i.e., progressive disease stages and expression of relevant molecular markers) and is a viable translational model.
Authors: Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese Journal: J Clin Oncol Date: 2011-09-12 Impact factor: 44.544
Authors: Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin Journal: Science Date: 2007-07-06 Impact factor: 47.728
Authors: Martien A M Groenen; Alan L Archibald; Hirohide Uenishi; Christopher K Tuggle; Yasuhiro Takeuchi; Max F Rothschild; Claire Rogel-Gaillard; Chankyu Park; Denis Milan; Hendrik-Jan Megens; Shengting Li; Denis M Larkin; Heebal Kim; Laurent A F Frantz; Mario Caccamo; Hyeonju Ahn; Bronwen L Aken; Anna Anselmo; Christian Anthon; Loretta Auvil; Bouabid Badaoui; Craig W Beattie; Christian Bendixen; Daniel Berman; Frank Blecha; Jonas Blomberg; Lars Bolund; Mirte Bosse; Sara Botti; Zhan Bujie; Megan Bystrom; Boris Capitanu; Denise Carvalho-Silva; Patrick Chardon; Celine Chen; Ryan Cheng; Sang-Haeng Choi; William Chow; Richard C Clark; Christopher Clee; Richard P M A Crooijmans; Harry D Dawson; Patrice Dehais; Fioravante De Sapio; Bert Dibbits; Nizar Drou; Zhi-Qiang Du; Kellye Eversole; João Fadista; Susan Fairley; Thomas Faraut; Geoffrey J Faulkner; Katie E Fowler; Merete Fredholm; Eric Fritz; James G R Gilbert; Elisabetta Giuffra; Jan Gorodkin; Darren K Griffin; Jennifer L Harrow; Alexander Hayward; Kerstin Howe; Zhi-Liang Hu; Sean J Humphray; Toby Hunt; Henrik Hornshøj; Jin-Tae Jeon; Patric Jern; Matthew Jones; Jerzy Jurka; Hiroyuki Kanamori; Ronan Kapetanovic; Jaebum Kim; Jae-Hwan Kim; Kyu-Won Kim; Tae-Hun Kim; Greger Larson; Kyooyeol Lee; Kyung-Tai Lee; Richard Leggett; Harris A Lewin; Yingrui Li; Wansheng Liu; Jane E Loveland; Yao Lu; Joan K Lunney; Jian Ma; Ole Madsen; Katherine Mann; Lucy Matthews; Stuart McLaren; Takeya Morozumi; Michael P Murtaugh; Jitendra Narayan; Dinh Truong Nguyen; Peixiang Ni; Song-Jung Oh; Suneel Onteru; Frank Panitz; Eung-Woo Park; Hong-Seog Park; Geraldine Pascal; Yogesh Paudel; Miguel Perez-Enciso; Ricardo Ramirez-Gonzalez; James M Reecy; Sandra Rodriguez-Zas; Gary A Rohrer; Lauretta Rund; Yongming Sang; Kyle Schachtschneider; Joshua G Schraiber; John Schwartz; Linda Scobie; Carol Scott; Stephen Searle; Bertrand Servin; Bruce R Southey; Goran Sperber; Peter Stadler; Jonathan V Sweedler; Hakim Tafer; Bo Thomsen; Rashmi Wali; Jian Wang; Jun Wang; Simon White; Xun Xu; Martine Yerle; Guojie Zhang; Jianguo Zhang; Jie Zhang; Shuhong Zhao; Jane Rogers; Carol Churcher; Lawrence B Schook Journal: Nature Date: 2012-11-15 Impact factor: 49.962
Authors: Ahmed O Kaseb; Lianchun Xiao; Manal M Hassan; Young Kwang Chae; Ju-Seog Lee; Jean-Nicolas Vauthey; Sunil Krishnan; Sheree Cheung; Hesham M Hassabo; Thomas Aloia; Claudius Conrad; Steven A Curley; John M Vierling; Prasun Jalal; Kanwal Raghav; Michael Wallace; Asif Rashid; James L Abbruzzese; Robert A Wolff; Jeffrey S Morris Journal: J Natl Cancer Inst Date: 2014-05-09 Impact factor: 13.506
Authors: K S Siveen; A H Nguyen; J H Lee; F Li; S S Singh; A P Kumar; G Low; S Jha; V Tergaonkar; K S Ahn; G Sethi Journal: Br J Cancer Date: 2014-08-07 Impact factor: 7.640
Authors: Lobna Elkhadragy; Kimia Dasteh Goli; William M Totura; Maximillian J Carlino; Maureen R Regan; Grace Guzman; Lawrence B Schook; Ron C Gaba; Kyle M Schachtschneider Journal: Front Oncol Date: 2022-05-20 Impact factor: 5.738
Authors: Kyle M Schachtschneider; Regina M Schwind; Jordan Newson; Nickolas Kinachtchouk; Mark Rizko; Nasya Mendoza-Elias; Paul Grippo; Daniel R Principe; Alex Park; Nana H Overgaard; Gregers Jungersen; Kelly D Garcia; Ajay V Maker; Laurie A Rund; Howard Ozer; Ron C Gaba; Lawrence B Schook Journal: Front Oncol Date: 2017-08-23 Impact factor: 6.244
Authors: Abedul Haque; Vishal Sahu; Jamie Lynne Lombardo; Lianchun Xiao; Bhawana George; Robert A Wolff; Jeffrey S Morris; Asif Rashid; John J Kopchick; Ahmed O Kaseb; Hesham M Amin Journal: J Hepatocell Carcinoma Date: 2022-08-15
Authors: Kyle M Schachtschneider; Regina M Schwind; Kwame A Darfour-Oduro; Arun K De; Lauretta A Rund; Kuldeep Singh; Daniel R Principe; Grace Guzman; Charles E Ray; Howard Ozer; Ron C Gaba; Lawrence B Schook Journal: Oncotarget Date: 2017-06-29
Authors: Ron C Gaba; Lobna Elkhadragy; F Edward Boas; Sulalita Chaki; Hanna H Chen; Mohammed El-Kebir; Kelly D Garcia; Eileena F Giurini; Grace Guzman; Francesca V LoBianco; Mario F Neto; Jordan L Newson; Aisha Qazi; Maureen Regan; Lauretta A Rund; Regina M Schwind; Matthew C Stewart; Faith M Thomas; Herbert E Whiteley; Jiaqi Wu; Lawrence B Schook; Kyle M Schachtschneider Journal: Oncotarget Date: 2020-07-14